Dr Reddy's Labs unit inks drug discovery, development pact with EQRx
The parties would share both fundings for the discovery and development of the programmes and financials resulting from the commercialisation of any eventual drug candidates, Aurigene stated.
New Delhi: Aurigene Discovery Technologies, a unit of Dr. Reddy's Laboratories, on Monday said it has inked a drug discovery, development, and commercialisation partnership with US-based EQRx. The collaboration combines Aurigene's small molecule drug discovery platform and EQRx's business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.
Read also: Dr Reddys acquires injectable product portfolio from Eton Pharma for Rs 391 crore
Aurigene is a clinical-stage biotech company based in Bangalore and Kuala Lumpur. Aurigene specializes in cancer and inflammatory disorders. Aurigene has fully integrated Drug Discovery & Development infrastructure from Hit Generation to Clinical Development.
Read also: Dr Reddys arm, Olema Pharma ink pact to develop novel cancer therapies
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd